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ABSTRACT
Objective: In this investigation, the amleorative role of esculetin (Esc) was investigated in gentamicin (Genta) nephrotoxicity in rats and the possible 
role of N-methyl-D-aspartate receptors (NMDAR) in genta-induced nephrotoxicity.
Methods: Genta (100 mg/kg/day, i.p. for 7 days) was administered to rats for the induction of nephrotoxicity, and subsequently, the extent of renal 
damage was measured by estimating creatinine clearance (CrCl), blood urea nitrogen (BUN), uric acid, microprotienuria and fractional excretion of 
sodium, and potassium. In addition, renal superoxide anion generation (SAG), Thiobarbituric acid reactive substance (TBARS), and reduced glutathione 
(GSH) level were used to evaluate renal oxidative parameters. Renal myeloperoxidase (MPO) activity was used to measure renal inflammation. D-serine, 
NMDA agonist was used in this study to evaluate the role of NMDA antagonist in genta-induced nephrotoxicity. Histopathological examination was 
performed using hematoxylin and eosin staining method.
Results: Genta-treated rats exhibited remarkable changes in renal parameters like increase in BUN, uric acid, microprotein fractional excretion of 
sodium and potassium with decrease in CrCl and similarly biochemical parameters like increase in SAG, thiobarbituric acid reactive species (TBARS), 
MPO activity with decrease in GSH level. Treatment with Esc (5 and 10 mg/kg/day, i.p for 7 days), NMDAR antagonist attenuated the genta-induced 
nephrotoxicity but did not shown significant effect on combined use of genta and D-serine treated group. Histopathological examination of genta-
treated rats. The coadministration of Esc + genta-protected kidney tissue from nephrotoxic effect of genta as illustrated by normalization of tubules 
but not with the combined use of Esc + genta + D-serine treated rats.
Conclusion: Esc displayed protective effect in genta-induced nephrotoxicity but combined effect of Esc + genta + D-serine abolished the protective 
effect of Esc thus confirming that NMDAR may be involved in genta-induced nephrotoxicity.
Keywords: Nephrotoxicity, Gentamicin, D-serine, Esculetin, N-methyl-D-aspartate receptor.
INTRODUCTION
Nephrotoxicity occurs when kidney-specific detoxification and 
excretion do not work properly due to the damage or destruction of 
kidney function by exogenous or endogenous toxicants [1]. Gentamicin 
(Genta) is one of the most effective aminoglycoside antibiotics used 
against Gram-negative infections. However, nephrotoxicity is the 
major untoward outcome of genta treatment. Recent reports suggest 
that 30% of the patients treated with genta for more than 7 days 
develop nonoligouric renal dysfunction and results in apoptosis as 
well as necrosis of tubular epithelial cells [2,3]. The occurrence of 
nephrotoxicity with genta is up to 60% in case of patients admitted in 
intensive care units [4].
N-methyl-D-aspartate receptors (NMDARs) belong to a class of 
ionotropic glutamate receptors that also include the α‐amino‐3‐
hydroxy-5-methylisoxazole-4-propionic acid receptors and kainate 
receptors [5]. NMDAR is glutamate-gated cation channel with high 
calcium permeability and critical for the development of the central 
nervous system [6]. NMDARs are also expressed across a wide 
spectrum of non-neuronal cells, including central and peripheral glial 
cells, endothelium, kidney, bone, pancreas, and others [5]. NMDAR 
forms a heterotetramer composed of NR1 and NR2 (A-D) subunits 
and more rarely, NR3 subunits [7]. The NR1 subunit is the main 
subunit of the NMDAR essential for channel activity, whereas the NR2 
subunits, although not essential for function, can confer modulatory 
properties [8]. NR1 is present in total rat kidney, cortex, and medulla 
and out of the NR2 subunits, only the NR2C subunit protein is present 
in the kidney [9].
Esculetin (Esc) is a coumarin derivative contained in many plants, 
such as Artemisia capillaris (Compositae), the leaves of Citrus limonia 
(Rutaceae), and Ceratostigma willmottianum [10,11] that are used as 
folk medicines. Various studies have reported Esc to possess antioxidant, 
antitumor, neuroprotective, and anti-inflammation activities [12]. 
Esc has been reported to inhibit NMDA neurotoxicity by modulating 
the expression of NMDA [13]. The renoprotective role of NMDA 
antagonist has been suggested in ischemia-reperfusion-induced renal 
dysfunction [14] and drug-induced renal dysfunction [8]. Recently, the 
renoprotective role of Esc has been evinced in streptozotocin induced 
diabetic rats [15,16]. Therefore, Esc was selected to evaluate its efficacy 
in genta-induced nephrotoxicity and its effect as NMDAR antagonist.
D-serine was used as a NMDA agonist in this study. It is relevant 
endogenous NMDAR ligand which act as coagonist at “glycine site” 
of NR1 subunit [17]. Therefore, this study has been designed to 
evaluate the role Esc mediated renoprotection against genta-induced 
nephrotoxicity and possible involvement of NMDAR.
METHODS
Animals
Sprague Dawley rats weighing (200-250 g) of age 3-5 months (National 
institute of Pharmaceutical Education and Research, Mohali, Punjab, 
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India) were employed in this study. Animals were provided with 
standard laboratory feed (Ashirwad Industries, Tirpari, Kharar District, 
Mohali, Punjab, India) and clean drinking water ad libitum and were 
exposed to natural cycle of light and dark. The experimental protocol 
was approved by the Institutional Animal Ethics Committee and care 
of the animals were taken as per the guidelines of Committee for 
the Purpose of Control and Supervision of Experiments on Animals 
(CPCSEA), Ministry of Environment and Forest Government of India 
(1201/9/08/CPCSEA/013).
Drugs and chemicals
Esc and D-serine were purchased from Sigma-Aldrich and Himedia 
Laboratories Pvt. Ltd., India. Genta was obtained from Nitin Life 
sciences Ltd., India. Eosin and haematoxylin were procured from 
S.D. Fine Chemicals Ltd., India. Dithiobis nitro benzoic acid, reduced 
glutathione (GSH), and nitro blue tetrazolium were obtained from Loba 
Chemie, India. All other reagents used in the study were of analytical 
grade.
Induction of nephrotoxicity
The nephrotoxicity in rats was induced by administering genta at a dose 
of 100 mg/kg; i.p. for 7 days [18,19]. Animals were placed in metabolic 
cages for urine collection. On 8th day, animals were anesthetized using 
diethyl ether. The blood samples were collected using retro-orbital 
puncture, and rats were sacrificed by cervical dislocation. The plasma 
isolated from blood was used for estimation of creatinine, blood urea 
nitrogen (BUN), uric acid, sodium and potassium level. Moreover, 
the creatinine, sodium, potassium, and protein content in urine 
were estimated. The kidneys were removed and washed with 1.17% 
potassium chloride (KCl) solution. A part of renal tissue was preserved 
in neutral buffered formalin for histological studies. A small portion 
was used for estimation of superoxide anion generation (SAG), and 
the rest of tissue was minced and homogenized (10% w/v) in 1.17% 
KCl solution using teflon homogenizer. The contents were centrifuged 
at 800 g for 20 minutes. The pellet obtained was used for estimation 
of myeloperoxidase (MPO) activity, whereas the clear supernatant was 
used to estimate lipid peroxides and reduced GSH levels.
Estimation of creatnine clearance
The estimation of creatinine in plasma and urine samples was done by 
using commercially available kit by ERBA Diagnostics Pvt. Ltd., India.
Estimation of BUN level
The BUN level was estimated in plasma by using commercially available 
kit by Meril Diagnostics Pvt. Ltd., India.
Estimation of plasma uric acid level
The uric acid was estimated in the plasma sample using commercially 
available kit by ADI Diagnostics Pvt. Ltd., India.
Estimation of fractional excretion of sodium
The sodium level was estimated in the plasma and urine samples by 
using commercially available kit by Reckon Diagnostics Pvt. Ltd., India.
Estimation of fractional excretion of potassium
The potassium level was estimated in the plasma and urine samples by 
using commercially available kit by Reckon Diagnostics Pvt. Ltd., India.
Estimation of microproteinuria
The microproteins were estimated in urine samples by using 
commercially available kit by ERBA Diagnostics Pvt. Ltd., India.
Estimation of MPO activity
The MPO activity which is measured as an index of neutrophil 
accumulation was measured using method of Bradley et al. [20].
Estimation of thiobarbituric acid reactive substance
The quantitative measurement of thiobarbituric acid reactive 
substances (TBARS), an index of lipid peroxidation in renal tissue was 
performed according to method of Ohkawa et al. [21].
Estimation of total protein content
The total protein content was determined using Lowry’s method [22] 
using bovine serum albumin as a standard.
Estimation of SAG
The SAG in the renal tissue has been evaluated using method described 
by Wang et al. [23].
Hematoxylin and eosin staining
The renal tissues preserved in 10% formalin were dehydrated in graded 
concentrations of ethanol, immersed in xylene and then embedded in 
paraffin. The sections of 4 µm thickness were cut and placed on slide 
using commercial Baker’s mounting fluid. Paraffin wax was removed by 
warming the slide gently, until the wax melted and then was washed 
with xylene. This was followed by washings with absolute alcohol 
and water to hydrate the sections and stained with haematoxylin and 
eosin described by Clayden [24]. The hydrated sections were stained 
with hematoxylin for 15 minutes. The stained sections were washed 
with water and treated with 1% acid alcohol mixture for 20 seconds. 
The acid alcohol mixture was washed off with water, and sections 
were counterstained with 1% aqueous solution of eosin for 2 minutes. 
After washing with water to remove excess of eosin, the sections 
were dehydrated using absolute alcohol and then mounted using 
Canada balsam as mounting agent. The slides were observed for gross 
histopathological changes and neutrophil accumulation.
Experimental protocol
About 6 groups were employed in the present study, each comprising 
6 rats.
Group I (control)
Animals were exposed to normal conditions for 7 days.
Group II (Esc per se)
Animals in this group were administered Esc (10 mg/kg; i.p.) for 7 days.
Group III (genta)
Animals in this group were treated with genta (100 mg/kg; i.p.) for 
7 days.
Group IV (genta + Esc 5 mg/kg)
Animals were treated with Esc (5 mg/kg; i.p.) 1 hr before the 
administration of genta (100 mg/kg; i.p.) for 7 days.
Group V (genta + Esc 10 mg/kg)
Animals were treated with Esc (10 mg/kg; i.p.) 1 hr before the genta 
(100 mg/kg; i.p.) administration for 7 days.
Group VI (D-serine + genta + Esc 10 mg/kg)
D-serine (80 mg/kg; i.p.) was administered to animals for 7 days 
followed by the similar treatment as mentioned in Group V.
Statistical analysis
Results were expressed as mean ± standard error of mean. The data 
obtained from various groups was statistically analysed using one-
way ANOVA followed by Tukey’s multiple range test. The p<0.05 was 
considered to be statistically significant.
RESULTS
Effect of various pharmacological interventions on creatinine 
clearance (CrCl)
The administration of genta (100 mg/kg; i.p. for 7 days) produces 
significant decrease in CrCl, when compared to control rats. The 
administration of Esc per se (10 mg/kg; i.p. for 7 days) did not show 
any significant effect on CrCl. The administration of Esc (5 mg/kg; 
i.p.; 10 mg/kg; i.p.) for 7 days to genta-treated rats; attenuated genta 
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decreased level of CrCl. The administration of D-serine (80 mg/kg i.p.) + 
Esc (10 mg/kg; i.p.) + genta (100 mg/kg i.p.) for 7 days did not produce 
significant effect on CrCl (Fig. 2).
Effect of various pharmacological interventions on BUN level
The administration of genta (100 mg/kg; i.p. for 7 days) produces 
significant increase in BUN level, when compared to control rats. The 
administration of Esc per se (10 mg/kg; i.p. for 7 days) did not show 
any significant effect on BUN level. The administration of Esc (5 mg/kg; 
i.p.; 10 mg/kg; i.p.) for 7 days to genta-treated rats; attenuated genta 
increased level of BUN. The administration of D-serine (80 mg/kg; 
i.p.) + Esc (10 mg/kg; i.p.) + genta (100 mg/kg; i.p.) for 7 days did not 
produce significant effect on BUN level (Fig. 3).
Effect of various pharmacological interventions on plasma uric 
acid level
The administration of genta (100 mg/kg; i.p. for 7 days) produces 
significant increase in plasma uric acid level, when compared to control 
rats. The administration of Esc per se (10 mg/kg; i.p. for 7 days) did not 
show any significant effect on plasma uric acid level. The administration 
of Esc (5 mg/kg; i.p.; 10 mg/kg; i.p.) for 7 days to genta-treated rats; 
attenuated genta increased level of plasma uric acid. The administration 
of D-serine (80 mg/kg i.p.) + Esc (10 mg/kg; i.p.) + genta (100 mg/kg 
i.p.) for 7 days did not produce significant effect on plasma uric acid 
level (Fig. 4).
Fig. 2: Effect of various pharmacological interventions on 
creatinine clearance. Esculin (LD): Esculetin low dose (5 mg/kg, 
i.p.), Esculin (HD): Esculetin high dose (10 mg/kg, i.p.), values are 
expressed as mean ± standard error of mean (STDEV), n=6, one-
Way ANOVA followed by Tukey’s multiple range test. *p<0.005 
as compared to control. **p<0.005 as compared to Gentamicin-
treated group. ***p<0.005 as compared to esculetin high-dose 
treated group
Fig. 3: Effect of various pharmacological interventions on blood 
urea nitrogen level. Esculin (LD): Esculetin low dose (5 mg/kg, 
i.p.), Esculin (HD): Esculetin high dose (10 mg/kg, i.p.), values are 
expressed as mean ± standard error of mean (STDEV), n=6, one-
Way ANOVA followed by Tukey’s multiple range test. *p<0.005 
as compared to control. **p<0.005 as compared to Gentamicin-
treated group. ***p<0.005 as compared to esculetin high-dose 
treated group
Fig. 4: Effect of various pharmacological interventions on plasma 
uric acid level. Esculin (LD): Esculetin low dose (5 mg/kg, i.p.), 
Esculin (HD): Esculetin high dose (10 mg/kg, i.p.), values are 
expressed as mean ± standard error of mean (STDEV), n=6, one-
Way ANOVA followed by Tukey’s multiple range test. *p<0.005 
as compared to control. **p<0.005 as compared to Gentamicin-
treated group. ***p<0.005 as compared to esculetin high-dose 
treated group
Fig. 1: Histopathological investigation, (a) normal control: 
Glomerular capillaries (black arrow) with both PCT (green 
arrow) and DCT (blue arrow) appears normal, (b) gentamicin 
treated group. Intestitial oedema seen by separation of tubules 
as well as congestion of capillaries. Tubules show epithelial 
degeneration, severe necrosis (red) and glomerular capillaries 
are widened (black), (c) esculetin (5 mg/kg) treated group: The 
histological features are improved as compared to gentamicin 
treated group. Glomerular capillaries retain their normal 
appearance and tubular epithelium is diminished, (d) esculetin 
(10 mg/kg/day) treated group: The histological features greatly 
improved and come to their normal structure of glomerular 
capillaries and tubular epithelium, (e) D-serine (80 mg/kg) + 
gentamicin (100 mg/kg) + escultein (10 mg/kg) treated group: 
The histopathological feature witnessed tubular necrosis (black 
arrow), interstitial edema and cluster of inflammatory cells 
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Effect of various pharmacological interventions on 
microproteinuria
The administration of genta (100 mg/kg; i.p. for 7 days) produces 
significant increase in microproteinuria level, when compared to 
control rats. The administration of Esc per se (10 mg/kg; i.p. for 7 days) 
did not show any significant effect on microproteinuria level. The 
administration of Esc (5 mg/kg; i.p.; 10 mg/kg; i.p.) for 7 days to genta-
treated rats; attenuated genta increased level of microproteinuria. 
The administration of D-serine (80 mg/kg i.p.) + Esc (10 mg/kg; i.p.) + 
genta (100 mg/kg i.p.) for 7 days did not produce significant effect on 
microproteinuria level (Fig. 5).
Effect of various pharmacological interventions on FeK
The administration of genta (100 mg/kg; i.p. for 7 days) produces 
significant increase in FeK level, when compared to control rats. The 
administration of Esc per se (10 mg/kg; i.p. for 7 days) did not show 
any significant effect on FeK level. The administration of Esc (5 mg/kg; 
i.p.; 10 mg/kg; i.p.) for 7 days to genta-treated rats; attenuated genta 
increased level of FeK. The administration of D-serine (80 mg/kg i.p.) + 
Esc (10 mg/kg; i.p.) + genta (100 mg/kg i.p.) for 7 days did not produce 
significant effect on FeK level (Fig. 6).
Effect of various pharmacological interventions on FeNa
The administration of genta (100 mg/kg; i.p. for 7 days) produces 
significant increase in FeNa level, when compared to control rats. 
The administration of Esc per se (10 mg/kg; i.p. for 7 days) did 
not show any significant effect on FeNa level. The administration of 
Esc (5 mg/kg; i.p.; 10 mg/kg; i.p.) for 7 days to genta-treated rats; 
attenuated genta increased level of FeNa. The administration of D-serine 
(80 mg/kg i.p.) + Esc (10 mg/kg; i.p.) + genta (100 mg/kg i.p.) for 7 days 
did not produce significant effect on FeNa level (Fig. 7).
Effect of various pharmacological interventions on TBARS
The administration of genta (100 mg/kg; i.p. for 7 days) produces 
significant increase in TBARS level, when compared to control rats. The 
administration of Esc per se (10 mg/kg; i.p. for 7 days) did not show any 
significant effect on TBARS level. The administration of Esc (5 mg/kg; 
i.p.; 10 mg/kg; i.p.) for 7 days to genta-treated rats; attenuated genta-
increased level of TBARS. The administration of D-serine (80 mg/kg i.p.) 
+ Esc (10 mg/kg; i.p.) + genta (100 mg/kg i.p.) for 7 days did not produce 
significant effect on TBARS level (Fig. 8).
Effect of various pharmacological interventions on GSH level
The administration of genta (100 mg/kg; i.p. for 7 days) produces 
significant decrease in GSH level, when compared to control rats. 
The administration of Esc per se (10 mg/kg; i.p. for 7 days) did 
not show any significant effect on GSH level. The administration of 
Esc (5 mg/kg; i.p.; 10 mg/kg; i.p.) for 7 days to genta-treated rats; 
attenuated genta decreased level of GSH level. The administration of 
D-serine (80 mg/kg i.p.) + Esc (10 mg/kg; i.p.) + genta (100 mg/kg i.p.) 
for 7 days did not produce significant effect on GSH level (Fig. 9).
Effect of various pharmacological interventions on MPO activity
The administration of genta (100 mg/kg; i.p. for 7 days) and D-serine 
(80 mg/kg; i.p. for 7 days) produces significant increase in MPO 
Fig. 5: Effect of various pharmacological interventions on 
microproteinuria. Esculin (LD): Esculetin low dose (5 mg/kg, i.p.), 
Esculin (HD): Esculetin high dose (10 mg/kg, i.p.), values are 
expressed as mean ± standard error of mean (STDEV), n=6, 
one-Way ANOVA followed by Tukey’s multiple range test. 
*p<0.005 as compared to control. **p<0.005 as compared to 
Gentamicin-treated group. ***p<0.005 as compared to esculetin 
high-dose treated group
Fig. 6: Effect of various pharmacological interventions fractional 
excretion of potassium (FeK). Esculin (LD): Esculetin low dose (5 
mg/kg, i.p.), Esculin (HD): Esculetin high dose (10 mg/kg, i.p.), 
values are expressed as mean ± standard error of mean (STDEV), 
n=6, one-Way ANOVA followed by Tukey’s multiple range test. 
*p<0.005 as compared to control. **p<0.005 as compared to 
Gentamicin-treated group. ***p<0.005 as compared to esculetin 
high-dose treated group
Fig. 7: Effect of various pharmacological interventions on 
fractional excretion of sodium (FeNa). Esculin (LD): Esculetin low 
dose (5 mg/kg, i.p.), Esculin (HD): Esculetin high dose (10 mg/kg, 
i.p.), values are expressed as mean ± standard error of mean 
(STDEV), n=6, one-Way ANOVA followed by Tukey’s multiple 
range test. *p<0.005 as compared to control. **p<0.005 as 
compared to Gentamicin-treated group. ***p<0.005 as compared 
to esculetin high-dose treated group
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administration of Esc per se (10 mg/kg; i.p. for 7 days) did not show 
any significant effect on SAG level. The administration of Esc (5 mg/kg; 
i.p.; 10 mg/kg; i.p.) for 7 days to genta-treated rats; attenuated genta 
increased level of SAG. The administration of D-serine (80 mg/kg i.p.) + 
Esc (10 mg/kg; i.p.) + genta (100 mg/kg; i.p.) for 7 days did not produce 
significant effect on SAG level (Fig. 11).
DISCUSSION
This study is based on ameliorative role of Esc-mediated renoprotection 
against genta-induced nephrotoxicity and possible involvement of 
NMDAR. genta is an antibiotic that exhibits a broad spectrum of activity 
and is particularly valuable in severe sepsis. Its use is, however, restricted 
because of the development of ototoxicity and nephrotoxicity [25,26]. 
Nephrotoxicity has been related to a selective accumulation of genta 
in the renal cortex and resulting morphologic lesions of proximal 
tubules [26,27] genta is associated with an induction of tubular 
necrosis, epithelial oedema of proximal tubules, cellular desquamation, 
Fig. 9: Effect of varoius pharmacological interventions on 
(reduced glutathione). Esculin (LD): Esculetin low dose (5 mg/kg, 
i.p.), Esculin (HD): Esculetin high dose (10 mg/kg, i.p.), values are 
expressed as mean ± standard error of mean (STDEV), n=6, one-
Way ANOVA followed by Tukey’s multiple range test. *p<0.005 
as compared to control. **p<0.005 as compared to Gentamicin-
treated group. ***p<0.005 as compared to esculetin high-dose 
treated group
Fig. 10: Effect of various pharmacological interventions on 
myeloperoxidase activity. Esculin (LD): Esculetin low dose 
(5 mg/kg, i.p.), Esculin (HD): Esculetin high dose (10 mg/kg, i.p.), 
values are expressed as mean ± standard error of mean (STDEV), 
n=6, one-Way ANOVA followed by Tukey’s multiple range test. 
*p<0.005 as compared to control. **p<0.005 as compared to 
Gentamicin-treated group. ***p<0.005 as compared to esculetin 
high-dose treated group
Fig. 11: Effect of various pharmacological interventions on 
superoxide anion generation. Genta - Gentamicin (100 mg/kg, 
i.p.), Esculin (LD): Esculetin low dose (5 mg/kg, i.p.), Esculin 
(HD): Esculetin high dose (10 mg/kg, i.p.), values are expressed 
as mean ± standard error of mean (STDEV), n=6, one-Way ANOVA 
followed by Tukey’s multiple range test. *p<0.005 as compared 
to control. **p<0.005 as compared to Gentamicin-treated group. 
***p<0.005 as compared to esculetin high-dose treated group
Fig. 8: Effect of various pharmacological interventions on 
thiobarbituric acid reactive oxygen substances. Esculin (LD): 
Esculetin low dose (5 mg/kg, i.p.), Esculin (HD): Esculetin high 
dose (10 mg/kg, i.p.), values are expressed as mean ± standard 
error of mean (STDEV), n=6, one-Way ANOVA followed by Tukey’s 
multiple range test. *p<0.005 as compared to control. **p<0.005 
as compared to Gentamicin-treated group. ***p<0.005 as 
compared to esculetin high-dose treated group
level, when compared to control rats. The administration of D-serine 
(80 mg/kg; i.p.) + genta (100 mg/kg; i.p.) for 7 days also produces 
significant increase in MPO level when compared to control rats. The 
administration of Esc per se (10 mg/kg; i.p. for 7 days) did not show 
any significant effect on MPO level. The administration of Esc (5 mg/kg; 
i.p.; 10 mg/kg; i.p.) for 7 days to genta-treated rats; attenuated genta-
increased level of MPO. The administration of D-serine (80 mg/kg i.p.) + 
Esc (10 mg/kg; i.p.) + genta (100 mg/kg i.p.) for 7 days did not produce 
significant effect on MPO level (Fig. 10).
Effect of various pharmacological interventions on SAG level
The administration of genta (100 mg/kg; i.p. for 7 days) produces 
significant increase in SAG level, when compared to control rats. The 
327
Asian J Pharm Clin Res, Vol 10, Issue 7, 2017, 322-328
 Bhatia et al. 
tubular fibrosis, glomerular congestion, perivascular edema and 
inflammation, which ultimately show the way to renal dysfunction [28], 
genta induces reactive oxygen free radicals mediated apoptosis [27] 
and endothelin-1, TXA2 and PAF mediated mesangial cells contraction 
that results in decreased GFR [29]. The exact mechanism underlying 
nephrotoxic behavior of genta is still not known.
In the present study, genta (100 mg/kg; i.p) was administred to Wistar 
rats for 7 days. After 7 days of administration of genta resulted in 
considerably renal damage. Histopathological examination of genta-
treated rats witnessed marked morphological changes including 
proximal and distal tubular damage, interstitial edema seen by sepration 
of tubular as well as congestion of capillaries, tubular show epithelial 
degeneration and severe necrosis as compared to control group (Fig. 1). 
Renal functions are important biomarkers to access nephrotoxicity. 
Genta-treated group showed significant changes in renal functions 
such as there was decreased level of CrCl, elevates BUN level, uric acid 
level, microproteinurea, fractional excretion of sodium, and potassium. 
The coadministration of Esc (5 mg/kg; 10 mg/kg) and genta showed 
increased level of CrCl and decreased elevated blood urera nitrogen 
and uric acid level and changes in fractional excretion of sodium 
and potassium levels where as combined effect of D-serine + genta + 
Escultin did not showed any significant changes in histopathological 
(Fig. 1) and renal parameters.
Genta-treated group also showed elevation in TBARS, SAG, MPO and 
reducing GSH levels suggesting oxidative stress and inflammation in 
genta-induced injury. The combined administration of Esc and genta 
significantly increased the activity of GSH and reduced elevated level 
of TBARS, SAG and MPO activity indicating that Esc has antioxidant 
activity by decreasing oxidative stress and has anti-inflammatory 
activity. However, combined effect of D-serine + genta + escultin 
abolished the above effects.
Esc (6,7-dihydroxycoumarin) has been reported to possesses NMDAR 
antagonist activity. NMDAR activation leads to opening of an ion 
channel that is selective for cations, resulting in the influx of Na+ 
and Ca2+ ions and efflux of K+ ions [30]. Excessive Ca2+ influx through 
NMDAR - coupled channels have been linked to cell death [31,32] and 
D-serine (D-Ser) used as NMDAR agonist which act at “glycine site” of 
NR1 subunit to mediate ion influx [17]. NMDAR subunit expression 
is increased in short-term genta animals and thus mediates renal 
damage [8]. Therefore, D-serine + genta + escultin did not show any 
significant results as D - serine abolished the effect of Esc.
Esc also reported to possesses analgesic, anti-inflammatory activity [33] 
by blocking NF-kB activation, by inhibiting the generation of ROS, by 
inhibiting LPS-induced nitric oxide and prostaglandin E2 production. It 
also significantly suppresses the production of inflammatory cytokines, 
including tumor necrosis factor‐α and interleukin‐1β [34] and in 
cocultured macrophages and adipocytes through up-regulation of 
heme oxygenase-1 (HO-1) [35]. Esc efficiently attenuated the oxidative 
stress induced cell damage via its antioxidant properties such as DPPH 
radical scavenging, hydroxyl radical scavenging, and intracellular 
ROS scavenging activities, also resulted in the protection of cells from 
lipid peroxidation, protein carbonyl, and DNA damage induced by 
H2O2 [12,36]. The renoprotective role of Esc against streptozotocin-
induced diabetic rats [15] and cisplatin-induced nephrotoxicity [37] has 
been attributed to its antioxidant activity and modulation of p53/Akt/
phosphatase and tensin homolog expression, respectively. Therefore 
with support from literature and data in hand, it may be suggested that 
Esc has shown amleorative effect in genta-induced nephrotoxicity.
The role of Esc in genta-induced nephrotoxicity and involvement of 
NMDAR was explored for the first time in this study. The administration 
of genta (100 mg/kg) for 7 days resulted in significant renal damage as 
indicated by decreased CrCl and increased levels of BUN, uric acid, FeNa, 
FeK, microproteinuria and significant rise in oxidative stress parameters 
TBARS, SAG and MPO along with depletion of GSH, an established 
indicator of antioxidant defense of the body. The treatment with Esc 
(5 mg/kg; 10 mg/kg) significantly attenuated genta-induced renal 
damage.
Hence, on the basis of above discussion, it is concluded that the 
treatment with Esc protects kidneys from genta-induced oxidative 
stress and dysfunction. Moreover, the administration of D-serine 
abolished the effect of Esc and thus indicating that NMDAR may be 
involved in the genta-induced nephrotoxicity.
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